Rigorous surveillance recommended after resection for HBV-related HCC in patients with metabolic syndromeOctober 24, 2022Hepatocellular Carcinoma
Blind spots require attention during abdominal ultrasonography-based HCC surveillanceOctober 24, 2022Hepatocellular Carcinoma
Microwave ablation: An alternative to resection in subcapsular HCC within the Milan criteriaOctober 24, 2022Hepatocellular Carcinoma
Antiplatelet therapy may decrease HCC incidence and improve post-treatment outcomesOctober 24, 2022Hepatocellular Carcinoma
Hepatectomy recommended for select patients with multiple HCCOctober 24, 2022Hepatocellular Carcinoma
Ramucirumab effective in patients with advanced HCC and AFP ≥400 ng/mL after non-sorafenib therapiesOctober 24, 2022Hepatocellular Carcinoma
Unresectable HCC: Atezolizumab plus bevacizumab proves its worth in the clinicOctober 24, 2022Hepatocellular Carcinoma
TARE vs TACE prolongs time to progression in HCC but not overall survivalSeptember 19, 2022Hepatocellular Carcinoma
Baseline DCP levels and NLR predict survival in patients receiving atezolizumab+bevacizumab for advanced HCCSeptember 19, 2022Hepatocellular Carcinoma
First-line lenvatinib+toripalimab+FOLFOX-HAIC shows promise in high-risk advanced HCCSeptember 19, 2022Hepatocellular Carcinoma
HCC: Averting post-TARE hepatic decompensation with careful patient selection September 19, 2022Hepatocellular Carcinoma
Postoperative adjuvant TACE efficacy in HCC depends on micronecrosis stateSeptember 19, 2022Hepatocellular Carcinoma
Unresectable HCC: Atezolizumab+bevacizumab more effective in patients with good liver functionSeptember 19, 2022Hepatocellular Carcinoma
